Novartis Cancer Drugs May Fight Ebola Virus, Study Shows

Two Novartis AG leukemia drugs, Gleevec and Tasigna, fought the deadly Ebola virus in laboratory experiments, suggesting the products could be used against a disease for which there are no treatments.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.